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Abstract 28 
Chronic hepatitis B, C and D virus (HBV, HCV and HDV) infections are a major cause of liver disease and cancer 29 
worldwide. Despite employing distinct replication strategies, the three viruses are exclusively hepatotropic and 30 
therefore depend on hepatocyte-specific host factors. The sodium taurocholate co-transporting polypeptide 31 
(NTCP), a transmembrane protein highly expressed in human hepatocytes that mediates the transport of bile acids, 32 
plays a key role in HBV and HDV entry into hepatocytes. Recently, NTCP has been shown to modulate HCV 33 
infection of hepatocytes by regulating innate antiviral immune responses in the liver. Here we review the current 34 
knowledge of the functional role and the molecular and cellular biology of NTCP in the life cycle of the three 35 
major hepatotropic viruses, highlight the impact of NTCP as an antiviral target and discuss future avenues of 36 
research. 37 
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Introduction 41 
Every year, viral hepatitis is estimated to cause around 1.3 million deaths worldwide, mainly through chronic liver 42 
disease and hepatocellular carcinoma (HCC). Approximately 95% of these deaths are caused by hepatitis B and C 43 
viruses (HBV, HCV) [1]. Despite the availability of an effective vaccine for HBV, 250 million people are 44 
chronically infected by the virus worldwide [2]. An estimated 5% of HBV patients are co-infected with hepatitis D 45 
virus (HDV), a satellite virus hijacking HBV envelope proteins to assemble its infectious viral particles. HDV co-46 
infection worsens the outcome of HBV infection and treatment of HBV-HDV co-infected patients is less effective 47 
[3, 4]. Moreover, around 70 million people are living with chronic HCV infection and, despite the existence of 48 
effective curative strategies, the incidence of HCV is still increasing [3].  49 
Remarkable progress has recently been made for treatment of HCV infection. The development and 50 
approval of direct acting antivirals (DAAs) specifically targeting viral proteins now allows for HCV cure, but these 51 
therapies remain inaccessible for the majority of HCV patients [5]. For chronic HBV infection, two therapeutic 52 
approaches are used to suppress viral replication: pegylated interferon and nucleos(t)ide analogues (NUCs). While 53 
these treatments allow control of HBV infection, viral eradication is rare and, in most cases, lifelong therapy is 54 
required [6]. For patients with chronic HBV/HDV co-infection, the current treatment options are limited to 55 
interferon-alpha (IFNα) and its pegylated derivative. Furthermore, although current antivirals decrease the risk of 56 
HCC, they are not sufficient to eliminate the risk [7, 8]. In order to effectively combat these hepatotropic viruses, 57 
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it is necessary to improve existing therapies and uncover new strategies for prevention and treatment of viral 58 
hepatitis.  59 
Alternative strategies against chronic HBV and HCV infection include host-targeting agents (HTA), 60 
which target host factors required for viral replication. HTAs have been shown to be promising candidates for the 61 
prevention and treatment of infections by various pathogens, including HBV and HCV [9–11]. This approach 62 
requires a profound understanding of the viral life cycle and the virus-host interactions involved. Indeed, the 63 
identification of the human sodium taurocholate co-transporting polypeptide (NTCP) as a functional receptor for 64 
HBV/HDV infection [12, 13] opened perspectives for new antiviral strategies. Several entry inhibitors for 65 
treatment of HBV infection targeting NTCP are now in development [14–19]. Furthermore, this crucial discovery 66 
has allowed the development of novel infectious model systems that will enable an improved understanding of the 67 
complete HBV/HDV viral life cycle [20]. However, the regulatory role of NTCP in HCV host cell infection, and 68 
its potential immunomodulatory activities in hepatocytes, should not be overlooked. The aim of this review is to 69 
summarize what is known about the interactions of NTCP with three major hepatitis viruses during infection, to 70 
describe the molecular mechanisms, and to highlight possible applications in research and therapy. 71 
 72 
Sodium taurocholate co-transporting polypeptide, a bile acid transporter 73 
The circulation of bile and bile components between human intestine enterocytes and liver parenchymal cells is 74 
known as the enterohepatic circulation (EHC) [21]. In the liver, bile acids are mainly involved in cholesterol 75 
metabolism and elimination of toxic compounds [22]. Interestingly, bile acids have also been shown to inhibit 76 
interferon (IFN) signaling pathways, resulting in reduced expression of IFN-stimulated genes (ISG) [23, 24]. In 77 
hepatocytes, bile acid homeostasis is maintained by the interplay between uptake, synthesis and secretion of bile 78 
acids. The major hepatic uptake transporter for conjugated bile acids in humans is sodium taurocholate 79 
co-transporting polypeptide (NTCP) [25]. NTCP is predominantly expressed at the hepatic basolateral membrane 80 
and is involved in the recycling of bile acids from portal blood to hepatocytes in a sodium-dependent manner [21]. 81 
NTCP is a member of the solute carrier family SLC10 and is encoded by SLC10A1 [26, 27]. SLC10A1 mRNA is 82 
translated into a 349 amino acid glycosylated phosphoprotein with seven or nine transmembrane domains [21, 28–83 
31]. While the exact function of some SLC10 family members remains unknown, all of them are thought to be 84 
sodium-dependent transporters [21]. Interestingly, bile acid transport through NTCP can be blocked by small 85 
molecules already in clinical use, such as cyclosporine A (CsA, an immunosuppressive drug used in 86 
transplantation) or ezetimibe (used for hypercholesterolemia) [16, 32]. 87 
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 Hepatic bile acid metabolism is tightly regulated, including at the transcriptional level (see Figure 1) [33]. 88 
Upon bile acid activation, the nuclear factor Farnesoid X Receptor (FXR) indirectly downregulates several target 89 
genes through transcriptional induction of the small heterodimer partner (SHP) [34, 35], including the first and 90 
rate-limiting enzyme in bile acid biosynthesis cholesterol 7α-hydroxylase (CYP7A1) [36, 37]. FXR also directly 91 
activates the expression of the bile salt export pump (BSEP, ABCB11), which is expressed at the apical membrane 92 
and secretes conjugated bile acids into the bile canaliculus in an ATP-dependent manner [38, 39]. FXR does not 93 
directly interact with the promoter of human SLC10A1 but induces the expression of different factors to indirectly 94 
repress slc10a1 expression in rat and mouse, although mechanisms of transcriptional regulation of human NTCP 95 
remain unknown [40–42]. In hepatic inflammation, the cytokines tumor necrosis factor alpha (TNF-α), interleukin 96 
(IL)-1β, and IL-6 downregulate mRNA levels of SLC10A1 and reduce the transporter protein expression [43–45]. 97 
The downregulation of NTCP expression in the human liver has been implicated in several cholestasis pathologies. 98 
The reduction of NTCP expression could explain impaired hepatic bile acid uptake, resulting in cholestatis and 99 
jaundice. Several studies have shown a downregulation of bile salt transporters in primary biliary cirrhosis [46, 100 
47]. Interestingly, a recent study showed a suppression of NTCP expression via cyclin D1 in hepatocellular 101 
carcinoma (HCC) [48]. These data may explain the low expression level of NTCP in HCC-derived cell lines, such 102 
as Huh7 and clones or HepG2.  103 
The localization and membrane expression of NTCP is controlled by post-translational mechanisms [49]. 104 
For example, cyclic adenosine monophosphate (cAMP) plays a role in stimulating the dephosphorylation and 105 
membrane translocation of NTCP (see Figure 1) [50–52]. Sequencing analysis of NTCP revealed the existence of 106 
several ethnic-dependent single nucleotide polymorphisms (SNPs) which may alter NTCP activities [53]. For 107 
example, mutation S267F, found in 7.5% of allele frequencies in Chinese Americans, is associated with an almost 108 
complete loss of bile acid uptake function. However, no pathologies have been described resulting from these 109 
NTCP polymorphisms and their clinical roles remain controversial [54]. Besides its major role in the bile acid 110 
uptake system, Yan et al. described the crucial role of NTCP on HBV and HDV entry [12]. For the time being, 111 
NTCP remains the only described HBV and HDV entry receptor. 112 
 113 
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NTCP is a host factor for HBV/HDV infection 115 
Hepatitis B virus is the prototypic member of the Hepadnaviridae family of small enveloped hepatotropic DNA 116 
viruses. Its envelope consists of three different forms of the HBV surface protein (HBsAg) – the small (S), middle 117 
(M) and large (L) proteins. Importantly, the preS1-domain of L envelope protein is known to bind the hepatocyte 118 
cell surface and is required for HBV and HDV entry [55]. The HBV capsid is comprised of HBV core protein 119 
(HBcAg) and encapsidates a partially double-stranded relaxed circular DNA (rcDNA) genome of 3.2 kilobases. 120 
Upon infection of hepatocytes, genomic rcDNA is converted into covalently closed circular DNA (cccDNA), a 121 
minichromosome-like structure that persists in the nucleus as a central transcription template for all viral RNAs 122 
[56]. The presence of cccDNA in the nucleus is thought to be responsible for viral rebound after withdrawal of 123 
NUC therapy that targets reverse transcription, a late step in the HBV life cycle. Therefore, removal of cccDNA 124 
from HBV-infected hepatocytes will be essential to achieve the goal of HBV cure [57]. 125 
HDV is a defective hepatotropic virus which depends on HBV surface proteins for assembly of infectious 126 
virions and viral entry [58]. The HDV genome is a negative single-stranded circular RNA of nearly 127 
1700 nucleotides containing one functional open reading frame, which encodes the hepatitis delta protein (HDAg) 128 
expressed in small and large form. Replication of HDV RNA and transcription of HDAg mRNA in the nucleus 129 
depends on host cell polymerases, including DNA-dependent RNA polymerase II. Both forms of the delta protein 130 
are then produced and reimported in the nucleus where they bind to genomic RNA to form the ribonucleoprotein 131 
(RNP), which is then exported into the cytoplasm and is associated with HBV envelope proteins to form a mature 132 
HDV virion [59]. Thus, HDV enters hepatocytes using the same pathways as HBV, and depends on the same host 133 
factors for host cell binding and entry. HDV is therefore a useful surrogate model for HBV entry. 134 
The first step of viral infection is virion binding to attachment factors and receptors at the host cell surface. 135 
This specific interaction between viral surface proteins and host entry receptors often determines the tissue tropism 136 
and host range of the virus [60]. HBV and its satellite virus HDV share HBV envelope proteins and are known to 137 
exclusively infect human, chimpanzee and tree shrew (Tupaia belangerii) hepatocytes, suggesting the involvement 138 
of species- and liver-specific cell surface factors in the common entry process of these viruses [20]. Two elements 139 
of the HBV envelope proteins are necessary for interaction with these factors. One determinant of infectivity 140 
resides in the surface-exposed cysteine-rich antigenic loop (AGL), a polypeptide located in the S domain of all 141 
three envelope proteins [61, 62]. The second known infectivity determinant is a receptor binding site in the N-142 
terminal pre-S1 domain of the L-HBsAg [55]. This domain is post-translationally modified by addition of myristic 143 
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acid [63], and this myristoylation is essential for virion infectivity [64, 65]. A synthetic myristoylated peptide 144 
comprising the N-terminal amino acids 2 to 78 of the pre-S1 domain prevents HBV infection [66].  145 
As for many viruses [67, 68], HBV/HDV infection requires the initial attachment to the 146 
glycosaminoglycan (GAG) side chains of heparan sulfate proteoglycans (HSPGs) [69]. Both the antigenic loop of 147 
all HBV envelope proteins and the preS1-region of HBsAg-L are involved in this interaction [69, 70]. Indeed, 148 
glypican-5 (GPC5), a member of the glypican family of HSPGs, acts as an entry factor for HBV and HDV (see 149 
Figure 2) [71]. After this initial step of HBV/HDV attachment to HSPGs, the virions bind to a high-affinity receptor 150 
via the preS1-domain [72], allowing uptake into hepatocytes. Despite the discovery of several preS1-interacting 151 
proteins that did not affect HBV infectivity [73–78], the identity of the HBV/HDV entry receptor remained unclear 152 
until 2012, when Yan et al. identified NTCP as a functional receptor for HBV and HDV infection. Using a labeled 153 
preS1 peptide as a bait in Tupaia hepatocytes, a mass spectrometry purification of preS1-bound proteins, and 154 
validation in human hepatocytes, it was shown that NTCP specifically interacts with the HBV receptor-binding 155 
domain preS1, allowing viral entry [12]. Zhong et al. showed that Tupaia NTCP mediates entry of woolly monkey 156 
HBV, indicating that NTCP orthologs act as a common cellular receptor for known primate hepadnaviruses [79]. 157 
Differential gene expression patterns between non-susceptible undifferentiated and susceptible differentiated 158 
HepaRG cells validated the role of NTCP as a specific receptor for HBV and HDV [13]. Moreover, silencing of 159 
NTCP in primary Tupaia hepatocytes (PTH) or differentiated HepaRG cells inhibits HBV and HDV infection [12, 160 
13]. Exogenous expression of NTCP directly renders non-susceptible hepatoma cell lines susceptible to HBV and 161 
HDV infection, while entry inhibitors derived from the preS1 peptide efficiently inhibit this infection [12]. In 162 
addition, the S267F mutant of NTCP, conferring a loss of bile acid uptake function, is significantly associated with 163 
resistance to chronic hepatitis B and decreased risk of cirrhosis and liver cancer development, supporting the role 164 
of NTCP as cellular receptor for HBV in human infection [80–82]. However, S267F homozygote patients can still 165 
be infected by HBV, suggesting the existence of alternative receptors allowing viral entry in the absence of 166 
functional NTCP [83]. 167 
Interestingly, expression of human (but not mouse) NTCP in non-susceptible hepatocarcinoma cells 168 
confers limited susceptibility to infection. For robust infection, addition of dimethyl sulfoxide (DMSO) to culture 169 
medium is essential [13]. The fact that human hepatoma cell lines HepG2 and Huh7 are not susceptible to HBV 170 
and HDV infection without exogenous expression of NTCP is consistent with reports that NTCP expression is 171 
reduced in human hepatocellular carcinoma cells [48, 84]. NTCP expression rapidly decreases over time following 172 
isolation of cultured PTHs, which supports observations that primary human hepatocytes (PHH) remain 173 
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susceptible to HBV infection in vitro only for a few days after isolation [12, 85]. Considering the predominant 174 
expression of NTCP in the liver, this receptor is likely to contribute to the hepatotropism of both viruses [12]. In 175 
addition, NTCP protein sequences vary among mammalian species, which might contribute to the narrow species 176 
tropism of HBV and HDV infection. For example, monkey NTCP does not support HBV and HDV infection 177 
despite a high protein sequence homology to human NTCP. Replacing amino acids 157–165 of nonfunctional 178 
monkey NTCP with the human counterpart conferred susceptibility to both HDV and HBV infection [12]. The 179 
fact that hepatocytes from cynomolgus and rhesus macaques and pigs become fully susceptible to HBV upon 180 
hNTCP expression indicates that NTCP is the key host factor limiting HBV infection in these species [86]. 181 
As a key host factor enabling HBV and HDV infection in vitro, the discovery of NTCP has been crucial 182 
for the development of novel animal models supporting virus infection. Indeed, only chimpanzees and Tupaia can 183 
experimentally support HBV and HDV infections [87]. The state-of-the-art mouse model for the study of 184 
HBV/HDV consists of liver-engrafted humanized chimeric uPa/SCID or FRG mice, which support virus entry and 185 
replication, but lack an efficient immune system, limiting the study of virus-host interactions [87]. The recent 186 
development of human NTCP-expressing transgenic mice opened perspectives for the development of novel 187 
immune-competent animal models for the investigation of HDV infection and HDV-induced pathogenesis in vivo 188 
[88]. As HBV infection is limited in mouse cells expressing hNTCP, probably due to the lack of a key host factor 189 
[89], it should be noted that hNTCP-transgenic mice are not susceptible to HBV infection. Recently, an elegant 190 
study demonstrated that vector-mediated expression of hNTCP in the hepatocytes of rhesus macaques conferred 191 
susceptibility to HBV infection, providing a robust and relevant model for the study of HBV infection, including 192 
its interaction with adaptive immunity and the understanding of viral clearance [90]. 193 
Overall, NTCP was identified as the long-sought preS1-specific HBV receptor contributing to HBV liver 194 
tropism and species specificity [13]. Targeting the interactions between the HBV preS1-domain and its receptor 195 
NTCP required for HBV/HDV entry is a promising strategy to block viral entry for both viruses. 196 
 197 
NTCP as a therapeutic target for HBV/HDV infection 198 
Even before the identification of NTCP as HBV/HDV receptor, entry inhibitors derived from the HBV preS1 were 199 
shown to efficiently inhibit HBV infection in vitro and in vivo [91, 92]. One of these compounds, the myristoylated 200 
preS1-derived peptide (also called Myrcludex B or MyrB), efficiently prevents HBV dissemination in vivo and 201 
hinders amplification of the cccDNA pool in infected human hepatocytes [14]. MyrB is the first HBV/HDV entry 202 
inhibitor targeting NTCP to reach clinical trials [93], where it was shown to have a good safety profile with a mild 203 
 8 
and reversible elevation of serum bile acid salts [93, 94]. Phase IIa clinical studies revealed a marked antiviral 204 
effect of MyrB, as measured by HDV RNA, HBV DNA and improvement of biochemical disease activity (ALT), 205 
when used in combination with IFN therapy, although there was no significant decrease in HBsAg levels. In 206 
monotherapy, however, MyrB did not show significant antiviral activity [94]. Further studies are necessary to 207 
confirm these results obtained in small patient cohorts [95].  208 
Importantly, the identification of NTCP as the first HBV/HDV entry receptor has accelerated the 209 
discovery and development of several new potential entry inhibitors. Binding of myristoylated preS1-derived 210 
peptide to NTCP was shown to interfere with the physiological bile acid transport function of NTCP, indicating 211 
that NTCP-inhibiting drugs might be able to block HBV infection [96]. In a study evaluating FDA approved 212 
therapeutics with documented inhibitory effect on NTCP cellular function against HDV entry, three of these 213 
molecules (irbesartan, ezetimibe, and ritonavir) inhibited HDV infection in vitro [97]. The inhibitory effect of 214 
ezetimibe on HBV infection had already been described previously without understanding its interactions with 215 
NTCP [98]. In 2014, Watashi et al. evaluated the effect of compounds on the early phase of the HBV life cycle to 216 
identify cyclosporine A as an HBV entry inhibitor targeting NTCP [15]. In the same year, Nkongolo et al. 217 
characterized the effect of cyclosporine A, a cholestasis-inducing drug inhibiting NTCP bile acid transport [32, 97, 218 
98], against HBV/HDV infection and found that inhibition of entry resulted from interference with the NTCP 219 
receptor [16]. The screening of FDA/EMA-approved drugs or small molecules for interaction with NTCP allowed 220 
the identification of several additional potential HBV/HDV entry inhibitors targeting NTCP [18, 19]. All of these 221 
NTCP-targeting HBV/HDV entry inhibitors concomitantly inhibit the transporter function of NTCP and impair 222 
bile acid uptake into hepatocytes, increasing the risk of adverse effects. NTCP-deficient mice and a patient with 223 
NTCP deficiency were shown to exhibit an elevated level of serum bile acids and to develop related pathologies 224 
including growth retardation and hypercholanemia [101, 102].  225 
Two different strategies to selectively inhibit HBV entry without impairing bile acid uptake have been 226 
suggested recently. Shimura et al. showed that cyclosporine A derivatives SCY450 and SCY995 inhibit 227 
HBV/HDV entry without interfering with the NTCP transporter activity (see Figure 2) [17]. Tsukuda et al. 228 
identified an oligomeric flavonoid, proanthocyanidin (PAC) and its analogs, as a new class of entry inhibitors, 229 
which directly target the preS1-domain of the HBV large envelope protein and thereby prevent its attachment to 230 
NTCP. By directly targeting HBV particles, PAC impairs HBV infectivity without affecting the NTCP-mediated 231 
bile acid transport activity [103]. Further studies are required to determine if these novel inhibitory strategies will 232 
show efficacy in vivo and in clinical studies in co-treatment with NUC therapy. 233 
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 234 
NTCP is a host factor for HCV infection 235 
Hepatitis C virus is an enveloped single-stranded positive-sense RNA virus in the Flaviviridae family. The 236 
host-cell derived lipid envelope contains the two viral envelope glycoproteins, E1 and E2 [104]. Within the 237 
envelope, an icosahedral capsid contains the RNA genome of 9.6 kilobases. Like HBV and HDV, attachment of 238 
HCV to hepatocytes is mediated by HPSGs on the host cell surface [105–107]. Following attachment, the envelope 239 
glycoprotein E2 mediates interactions with a series of specific cellular entry factors, including CD81 and claudin-240 
1 (see Figure 2) [108–111]. HCV is internalized via endocytosis in a clathrin- and dynamin-dependent process 241 
[112]. Following fusion with early endosomal membranes, the HCV genome is released into the cytosol, where it 242 
is translated into a polyprotein cleaved by viral and host proteases. The HCV genome is replicated directly into 243 
RNA without passing through a DNA intermediate [113]. Therefore, HCV entry and replication steps are very 244 
distinct from those described for HBV/HDV. Nonetheless, the mutual hepatotropism of these three viruses 245 
mediated by tissue specific factors suggests a possible overlap in usage of common hepatocyte specific host factors 246 
like NTCP. 247 
Following establishment of the pivotal role of NTCP for HBV and HDV entry into hepatocytes, a recent 248 
study identified a role for NTCP in HCV infection (see Figure 2). Exogenous overexpression or silencing of NTCP 249 
increased or decreased HCV infection in vitro, respectively [114]. Unlike HBV, however, no direct interaction 250 
between HCV envelope proteins and NTCP was identified. Instead, the bile acid transporter function of NTCP 251 
was found to be important for HCV entry [114]. Bile acids are known to modulate cellular antiviral responses by 252 
inhibiting interferon (IFN) type I signaling and thereby decreasing the expression of IFN-stimulated genes (ISGs) 253 
[23, 24]. NTCP was shown to regulate HCV infection by inducing the bile acid-mediated repression of ISG 254 
expression in hepatocytes, including IFITM1, IFITM2 and IFITM3 [114]. These transmembrane proteins are 255 
known to restrict the entry of several viruses, including HCV [115]. IFITM1 blocks the interaction between HCV 256 
and its receptors [116], whereas IFITM2 and IFITM3 inhibit entry at a post-endocytosis step by blocking the 257 
release of virions into the cytoplasm [117]. NTCP facilitates HCV infection by modulating innate antiviral 258 
responses via its bile acid transport function. As bile acids have been shown to enhance HCV replication [118], it 259 
is likely that NTCP expression and activity modulates HCV infection through a multimodal mechanism of action. 260 
Interestingly, MyrB-mediated inhibition of NTCP blocks the import of bile acids, which in turn stimulates the 261 
expression of ISGs, inhibiting HCV entry and infection [114]. However, it still needs to be determined whether 262 
the inhibition of NTCP-mediated bile acid entry affects the HBV life cycle through similar mechanisms as 263 
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described for HCV. The potential of NTCP-targeting antivirals to enhance innate antiviral responses and to engage 264 
the host immune system to clear infection may be a useful property for the treatment of all hepatotropic viruses, 265 
including HBV, HCV and HDV. 266 
 267 
Conclusions 268 
The discovery of NTCP as the first HBV/HDV receptor was a milestone in the study of the life cycle of these 269 
viruses. This landmark discovery enabled significant progress in understanding HBV/HDV entry and virus-host 270 
interactions. Moreover, based on this discovery, novel infectious model systems based on transduced cell lines 271 
stably expressing NTCP have been developed which allow detailed study of the early steps of the viral life cycle. 272 
By allowing the study of authentic infection in cell lines, these model systems will help to understand the formation 273 
and degradation of HBV cccDNA, which is a key target to achieve the ultimate goal of HBV cure. Robust human 274 
NTCP-expressing animal model systems will enable the in vivo validation of virus-host interactions and antiviral 275 
therapies. Moreover, NTCP has been established as an antiviral target, and several molecules targeting NTCP are 276 
in clinical development with the goal to improve current therapies in the future. The recent discovery of NTCP as 277 
a host-dependency factor in HCV infection underscores its essential role in virus-hepatocyte interactions.  278 
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Figure legends 629 
Fig. 1 Model of the functional role of NTCP in hepatic bile acid transport and metabolism. Transport of bile 630 
acids from portal blood into hepatocytes via NTCP depends on a sodium gradient and is inhibited by CsA or 631 
ezetimibe. Secretion into the bile canaliculus via bile salt export pump (BSEP) in an ATP-dependent manner and 632 
synthesis from cholesterol are regulated by bile acid-mediated activation of FXR. cAMP mediates 633 
dephosphorylation and membrane translocation of NTCP. NTCP: Sodium taurocholate co-transporting 634 
polypeptide; BSEP: bile salt export pump; FXR: Farnesoid X Receptor; SHP: small heterodimer partner; CYP7A1: 635 
cholesterol 7α-hydroxylase; BA: bile acid; TJ: tight junction; CsA: cyclosporin A; cAMP: cyclic adenosine 636 
monophosphate 637 
 638 
Fig. 2 Model of interactions between NTCP and the entry of HBV, HDV, and HCV in hepatocytes. After 639 
initial attachment to HSPG including GPC5, HBV and HDV virions bind to the receptor NTCP through the preS1-640 
domain of the large envelope protein. NTCP inhibitors CsA and ezetimibe block viral entry like preS1-derived 641 
MyrB and CsA-derived SCY995. NTCP modulates HCV infection by interfering with innate immune responses. 642 
Bile acids interfere with the IFN signaling pathway and thereby favor HCV entry. Inhibition of NTCP-mediated 643 
bile acid import into hepatocytes promotes inhibition of HCV entry through the upregulation of ISGs including 644 
IFITMs. HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus; HSPG: heparan sulfate 645 
proteoglycan; GPC5: glypican-5; NTCP: Sodium taurocholate co-transporting polypeptide; MyrB: myrcludex B; 646 
CsA: cyclosporin A; SCY995: synthesized CsA derivative 995; IFN: interferon; IFNAR: IFN-α/β receptor; JAK: 647 
Janus kinase; STAT: signal transducer and activator of transcription; IRF9: Interferon regulatory factor 9; ISRE: 648 
IFN-sensitive response element; ISG: IFN-stimulated gene; IFITM: IFN-induced transmembrane protein; CLDN1: 649 
Claudin 1; CD81: cluster of differentiation 81; BA: bile acid; TJ: tight junction 650 
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